Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Polypodium Leucotomos and Improved Repigmentation

Doses used in studies

mg/day: 750–960 (median 855, IQR 802.5–907.5) — 2 studies

Time to effect

Median: 5.9 months · IQR 5.9 months–6 months · Range 5.8 months–6 months — Reported in 2 of 2 studies

2 of 2 papers

NB-UVB plus oral Polypodium leucotomos extract display higher efficacy than NB-UVB alone in patients with vitiligo.
- 2021-02-05
- RCT · n = 21
- Dermatologic therapy 34(2)
- - Alessia Pacifico
  - Giovanni Damiani
  - Paolo Iacovelli
  - Rosalynn R Z Conic
  - Salvador Gonzalez
  - Aldo Morrone
- PubMed: 33433041
- DOI: 10.1111/dth.14776
2 Insights on
- Improved Repigmentation
- High evidence
- Clinical
Our results demonstrated that oral PL combined with NB-UVB improved repigmentation as well as increased the response rate compared with patients treated with NB-UVB alone (47.8% vs 22%).
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
480 mg twice daily
Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study.
- 2007-04-18
- RCT
- Journal of the European Academy of Dermatology and Venereology : JEADV 21(7)
- - M A Middelkamp-Hup
  - J D Bos
  - F Rius-Diaz
  - S Gonzalez
  - W Westerhof
- PubMed: 17659004
- DOI: 10.1111/j.1468-3083.2006.02132.x
5 Insights on
- Improved Repigmentation
- High evidence
- Clinical
Small repigmentation increases (P = n.s.) were observed for the trunk (6% increased repigmentation), extremities (4%), and hands and feet (5%) in the P. leucotomos group vs. placebo.
Effect
Neutral
Effect size
Small
Significant
No
Dose
250 mg three times daily